Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at UBS Group

UBS Group upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a neutral rating to a buy rating in a research report released on Thursday, Marketbeat.com reports. They currently have $978.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $660.00.

Several other brokerages have also issued reports on REGN. Jefferies Financial Group raised their target price on shares of Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Wells Fargo & Company upped their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Evercore raised their target price on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Finally, Truist Financial upped their target price on shares of Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $845.21.

Regeneron Pharmaceuticals Stock Down 0.7%

Shares of REGN opened at $790.74 on Thursday. The business’s fifty day moving average price is $791.72 and its two-hundred day moving average price is $721.78. The firm has a market capitalization of $81.41 billion, a price-to-earnings ratio of 19.54, a PEG ratio of 1.37 and a beta of 0.16. Regeneron Pharmaceuticals has a 52 week low of $566.11 and a 52 week high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter in the previous year, the company posted $12.81 earnings per share. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post 47.93 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, insider Andrew Murphy sold 4,147 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at $512,550. The trade was a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 8,093 shares of company stock worth $6,506,845. Company insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. IFP Advisors Inc grew its holdings in Regeneron Pharmaceuticals by 17.5% in the 3rd quarter. IFP Advisors Inc now owns 1,588 shares of the biopharmaceutical company’s stock valued at $1,204,000 after buying an additional 236 shares in the last quarter. Robertson Stephens Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $491,000. Frank Rimerman Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 153.7% in the third quarter. Frank Rimerman Advisors LLC now owns 1,446 shares of the biopharmaceutical company’s stock valued at $1,096,000 after acquiring an additional 876 shares during the period. Alpine Bank Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $34,000. Finally, USA Financial Formulas acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $743,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly performance supported the bullish case. Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and above analyst expectations. Earnings per share of $14.29 also exceeded the $10.16 consensus estimate, reinforcing confidence in the company’s earnings momentum. Regeneron earnings and investment narrative
• Positive Sentiment: Positive 84-week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva indicated a sustained reduction in new heterotopic bone lesions and disease flare-ups, with a generally consistent safety profile. The results could strengthen confidence in the treatment’s commercial opportunity. Regeneron OPTIMA trial results
• Positive Sentiment: UBS upgraded REGN to Buy and raised its price target to $978 from $660, citing greater long-term potential for Dupixent and arguing that the market may be undervaluing the business. UBS Regeneron upgrade
• Positive Sentiment: Libtayo received a positive recommendation from the European Medicines Agency’s CHMP for a dosing regimen that could reduce administration frequency from every three weeks to every six weeks after the first 12 weeks, potentially improving convenience and market appeal. Final EU approval is still required. Libtayo CHMP recommendation
• Negative Sentiment: Insider Andrew Murphy sold 4,147 shares worth approximately $3.2 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, limiting its significance, but it may contribute modestly to near-term caution. Regeneron insider sale filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.